Distinguished in Juvenile Temporal Arteritis

Anne-laure L. Fauchais

Limoges, FR 
Clinical Trials:Currently Recruiting for 2 Trials
Distinguished in Juvenile Temporal Arteritis
Limoges, FR 
OverviewLocationsClinical Research

Overview

Anne-laure Fauchais practices in Limoges, France. Fauchais is rated as a Distinguished expert by MediFind in the treatment of Juvenile Temporal Arteritis. Their top areas of expertise are Giant Cell Arteritis (GCA), Temporal Arteritis, Sjogren Syndrome, and Dry Mouth.

Their clinical research consists of co-authoring 72 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 20 articles in the study of Juvenile Temporal Arteritis.

Locations

Limoges, France
Other Locations
CHU Brest
Brest, France
Toulouse, France
Lille, France
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Phase II/III Double-blind Randomized Placebo-controlled Trial Assessing the Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk in Subjects With Specific Dysimmunity and Raynaud Phenomenon
Phase II/III Double-blind Randomized Placebo-controlled Trial Assessing the Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk in Subjects With Specific Dysimmunity and Raynaud Phenomenon
Enrollment Status: Recruiting
Publish Date: July 14, 2025
Intervention Type: Drug
Study Drug: Clopidogrel Treatment
Study Phase: Phase 2/Phase 3
Safety and Efficacy of Itacitinib in Adults with Systemic Sclerosis: a Phase II, Randomized, Controlled Trial
Safety and Efficacy of Itacitinib in Adults with Systemic Sclerosis: a Phase II, Randomized, Controlled Trial
Enrollment Status: Recruiting
Publish Date: September 26, 2024
Intervention Type: Drug
Study Drug: Itacitinib
Study Phase: Phase 2
Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases
Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases
Enrollment Status: Completed
Publish Date: February 03, 2022
Intervention Type: Biological
Primary Sjögren Syndrome
Primary Sjögren Syndrome
Enrollment Status: Completed
Publish Date: January 11, 2019
Intervention Type: Other
View 2 Less Clinical Trial

72 Total Publications

Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial.
Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial.
Journal: Annals of internal medicine
Published: July 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Fauchais's expertise for a condition
ConditionClose
    View All 25 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile